AstraZeneca and MSD have been collaborating for just under two years in oncology, and have so far enjoyed success in accelerating the progress of PARP inhibitor Lynparza. The tie-up is allowing both companies to bring more firepower to R&D and marketing of the drugs, including novel combination trials across their respective oncology portfolios. Today the spotlight has been turned on the other molecule in the co-development and co-commercialisation partnership, selumetinib, a MEK 1/2 inhibitor with potential across a range of targeted uses. The partners have just announced that the FDA has granted the two companies Breakthrough Therapy Designation (BTD) for selumetinib in a rare paediatric condition. The news is a welcome turn around for the molecule, which failed in a phase 3 trial in non-small cell lung cancer (NSCLC) back in 2016. Now the new niche setting could help AZ and MSD add another drug to their oncology armoury. There are several other MEK inhibitor drugs already on the market, including Novartis
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!